Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical minoxidil 5%
minoxidil 5% · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| DA-005 | EXPERIMENTAL | Oral Botanical Supplement HIF-1a inhibitor |
| Topical Minoxidil 5% | ACTIVE_COMPARATOR | Topical Minoxidil 5% |
| DA-002 | EXPERIMENTAL | Topical Alpha 1 Agonist |
| Name | Type | Description |
|---|---|---|
| DA-005 | DIETARY_SUPPLEMENT | Oral Botanical Supplement HIF-1a inhibitor |
| Topical minoxidil 5% | DRUG | Topical minoxidil 5% |
| DA-002 | DRUG | Topical Alpha 1 Agonist (GRAS) |
| Placebo Oral Tablet | DIETARY_SUPPLEMENT | Placebo Oral Tablet |
| Placebo Topical Solution | OTHER | Placebo Topical Solution |
Inclusion Criteria: * Age 18 or older * Diagnosed with androgenetic alopecia * Willing and able to apply the treatment as directed, comply with study * Otherwise healthy * Able to give informed consent Exclusion Criteria: * A medical history that may interfere with study objectives * Women who ar...
Minoxidil 5% is used for the treatment of androgenetic alopecia, which includes male pattern baldness and female pattern baldness. It is a topical small molecule being developed by Applied Therapeutics, Inc. for this dermatological condition.
Minoxidil 5% is a small molecule that works as a potassium channel opener, which is believed to promote hair growth by increasing blood flow to hair follicles and stimulating hair follicle cells. It is applied topically to treat androgenetic alopecia.
Minoxidil 5% is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting clinical trials to evaluate its efficacy in treating hair loss.
Minoxidil 5% is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to assess its safety and efficacy in patients with androgenetic alopecia.
Minoxidil 5% is being evaluated in a Phase 3 clinical trial with the identifier NCT06501924, titled "Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss." This randomized, double-blind, active-controlled study plans to enroll 516 participants with androgenetic alopecia, including male and female pattern baldness.
Yes, minoxidil 5% is also known as topical minoxidil 5%. The drug is administered topically and is being studied for the treatment of androgenetic alopecia. It is important to note that this is an investigational formulation being developed by Applied Therapeutics, Inc.